#Class Action #Faruqilaw #Baxter International

Baxter Investors Notified of Class Action Lawsuit

Faruqi & Faruqi, LLP, a prominent national securities law firm, has made an announcement reminding investors about a significant class action lawsuit against Baxter International Inc (NYSE: BAX). This legal action pertains to allegations concerning the integrity and safety of Baxter’s Novum LVP medical device. Investors affected by this issue and who suffered losses related to Baxter's securities from February 23, 2022, to July 30, 2025, are encouraged to assess their legal rights.

Context of the Lawsuit

In a formal statement, the firm’s Securities Litigation Partner, James (Josh) Wilson, has encouraged those affected by Baxter's performance to reach out for legal assistance. The call to action is particularly critical as the lead plaintiff deadline is set for December 15, 2025. The lawsuit stems from serious claims that Baxter's executives made misleading statements regarding the safety and efficacy of the Novum LVP (Large Volume Pump), which allegedly suffered from systemic defects leading to malfunctions of a critical nature.

The allegations are stark; defects in the Novum LVP reportedly caused severe problems such as under-infusion, over-infusion, and in some unfortunate cases, complete non-delivery of fluids. Such malfunction not only jeopardizes patients' health but has also led to injuries and even fatalities, raising alarms among healthcare professionals and patients alike.

Major Allegations

The crux of the allegations is that Baxter's response to the malfunctions was inadequate and that they concealed information from their customers and investors. It’s claimed that the company was aware of multiple malfunctions and logged injuries and deaths attributed to these defects but did not take sufficient action to rectify these dangerous issues. Moreover, it is suggested that the alerts issued by Baxter failed to address the underlying design flaws, leaving patients vulnerable.

Following a major revelation on July 31, 2025, the gravity of Baxter’s situation became apparent when the company announced a